Drug h is administered in an active form and converted to an inactive metabolite by cyp3a4. if drug h is administered to a patient who is an ultrarapid metabolizer, what is the likely outcome?
a) Increased therapeutic effect due to higher levels of active drug.
b) Decreased therapeutic effect due to higher levels of inactive metabolite.
c) Increased risk of toxicity due to higher levels of active drug.
d) Decreased risk of side effects due to rapid metabolism of the drug.
e) No significant change in therapeutic effect or side effects